Figure 2 FDA-approved therapeutics with CDx, including novel oncological therapies (1997-2024)

Biomarker use in oncology trials, by year (2015-24) Source: TrialTrove; L.E.K. research and analysis Rising BM use in trials has predictably had an impact on product launches, with the U.S. Food